TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2000827
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of treatment after day 28
Study: 25677920
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg daily for 48 hours)
Study: 16483435
Drug: Preoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative intravenous ampiclox and vitamin B complex
Study: 10935688
Drug: Ritonavir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (200 mg, four doses) with triazolam (0.125 mg)
Study: 10935688
Drug: Ritonavir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (200 mg, four doses) with zolpidem (5.0 mg)
Study: 10935688
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with triazolam (0.125 mg)
Study: 10935688
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with zolpidem (5.0 mg)
Study: 8848989
Drug: Transdermal clonidine
Normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal clonidine weekly
Study: 6366560
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Symptomatic treatment only)
Study: 24485080
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of gel of lidocaine 2% intrarectal with 50mg tramadol (2 tablets)
Study: 24485080
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of lidocaine 2% injected at the level of periprostatics laterals and apical areas
Study: 22791802
Drug: Saline-based tetrastarch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline-based tetrastarch HES infusion
Study: 22791802
Drug: Balanced solution-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced solution-based HES infusion
Study: 18060924
Drug: Standard Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Therapy Group
Study: 15943224
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg genistein
Study: 15943224
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg genistein
Study: 15943224
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg genistein
Study: 15943224
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg genistein
Study: 10435880
Drug: Pirenzepine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (100 mg p.o.) before GHRH injection
Study: 838992
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aerosol (BDA), 50 mug four times daily
Study: 25305230
Drug: Prophylactic cloxacillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic cloxacillin (2 g IV) or clindamycin (600 mg IV)
Study: 21267804
Drug: Piperacillin/tazobactam 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam 4.5 g i.v. (single-dose)
Study: 21267804
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg or cotrimoxazol 960 mg i.v./p.o. (5 days)
Study: 21267804
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (varied administration and duration of different antibiotics)
Study: 19799843
Drug: Alum-adjuvanted whole-virus
Normalized name: alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alum-adjuvanted whole-virus vaccine (45 microg)
Study: 19799843
Drug: Alum-adjuvanted whole-virus
Normalized name: alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alum-adjuvanted whole-virus vaccine (15 microg)
Study: 19799843
Drug: Alum-adjuvanted whole-virus
Normalized name: alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alum-adjuvanted whole-virus vaccine (5 microg)
Study: 19799843
Drug: Intradermal whole-virus
Normalized name: INFLUENZA A VIRUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal whole-virus vaccine
Study: 14728939
Drug: Rectal bleeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal bleeding with altered bowel habit
Study: 14728939
Drug: Isolated rectal
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated rectal bleeding
Study: 11297722
Drug: Fluoxetine (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (n = 16)
Study: 9106123
Drug: Selegiline (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (20 mg daily)
Study: 3794874
Drug: Single-dose gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose gentamicin therapy
Study: 3794874
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment for 10 days
Study: 22502816
Drug: Intermittent androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent androgen deprivation therapy (ADT)
Study: 22502816
Drug: Continuous androgen
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous androgen deprivation therapy (ADT)
Study: 15899109
Drug: Palonosetron 0.25mg
Normalized name: FOSNETUPITANT 235/PALONOSETRON 0.25MG/VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.25mg IV with aprepitant 125 mg on day 1 and 80 mg on days 2 and 3
Study: 12559781
Drug: Structured antiviral
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured antiviral drug treatment interruptions (STIs) with therapeutic HIV immunizations
Study: 12559781
Drug: Structured antiviral
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured antiviral drug treatment interruptions (STIs) without therapeutic HIV immunizations
Study: 1659189
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine (ddI) administered orally twice daily at a total daily dose of 750 mg or 1,500 mg for 12 weeks
Study: 6992834
Drug: Aromatic retinoid
Normalized name: Curcuma aromatica root oil
DrugBank: Curcuma aromatica root oil (DB11301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatic retinoid (Ro 10‐9359) orally (0.50‐0.66 mg/kg body weight) and placebo cream topically
Study: 6992834
Drug: Aromatic retinoid
Normalized name: Curcuma aromatica root oil
DrugBank: Curcuma aromatica root oil (DB11301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatic retinoid (Ro 10‐9359) orally (0.50‐0.66 mg/kg body weight) with 0.1% triamcinolone acetonide and 5% salicylic acid in lanette wax cream
Study: 6992834
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules with 0.1% triamcinolone acetonide and 5% salicylic acid in lanette wax cream
Study: 30745183
Drug: Psychoeducational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational therapy
Study: 23499440
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg plus peginterferon and ribavirin for 12 weeks (cohort A)
Study: 23499440
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg plus peginterferon and ribavirin for 24 weeks (cohort B)
Study: 23499440
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of sofosbuvir plus peginterferon and ribavirin followed by 12 weeks of either sofosbuvir monotherapy or sofosbuvir plus ribavirin (cohort C)
Study: 16758944
Drug: HHD with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HHD with 6% hydroxyethyl starch (HES) 130/0.4 solution, 15 ml/kg before anesthesia and 33 ml/kg intraoperatively
Study: 26951208
Drug: Edoxaban, with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban, with a 50% dose reduction in patients with low body weight (≤60 kg), moderate renal impairment (CLCR ≤50 mL/min), or concomitant P-glycoprotein inhibitors.
Study: 26951208
Drug: Edoxaban without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban without specified dose reduction.
Study: 22574572
Drug: Variable-frequency electroacupuncture
Normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable-frequency electroacupuncture (EA) combined with herbal-moxa moxibustion (15 cm roll, components include corydalis tuber, astragali radix, myrrh, etc.), applied to Jiaji (EX-B 2) and Ashi-point, once daily for 7 days.
Study: 22574572
Drug: Brufen (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brufen (0.3 g, b.i.d.), vitamin B1 (10 mg, t.i.d.), vitamin E (100 mg, b.i.d.)
Study: 22574572
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received treatment and assessed using the visual analog scale (VAS) for pain reaction.
Study: 19661237
Drug: Flexible VA-guided
Normalized name: VP/VA COPOLYMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible VA-guided regimen after three initial injections of ranibizumab
Study: 19661237
Drug: Monthly and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly and quarterly VA-guided regimens
Study: 15262458
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg/d with diet (S-D)
Study: 9151289
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of acetaminophen (oral dose)
Study: 3304479
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) alone for 4 months followed by chemotherapy + TAM
Study: 3304479
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) + chemotherapy simultaneously
Study: 3304479
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone for 8 months followed by TAM + chemotherapy
Study: 15256232
Drug: Keeping the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keeping the drain in until discharge had decreased to less than 40 ml/24 h
Study: 9362160
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (hydroxyurea or busulfan)
Study: 3320229
Drug: Both anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both anesthetic agents
Study: 28834259
Drug: Golimumab (tumor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab (tumor necrosis factor inhibitor), dosage not specified, duration 24 weeks
Study: 26291335
Drug: Vilazodone (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilazodone (20-40 mg/day)
Study: 21188521
Drug: Vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K1 (oral daily dose)
Study: 21188521
Drug: Vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K1 (intravenous weekly doses)
Study: 10901114
Drug: n-butyl acetate
Normalized name: n-butyl acrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-butyl acetate at 12 ppm (44 or 56 mg/m3)
Study: 10901114
Drug: n-butyl acetate
Normalized name: n-butyl acrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-butyl acetate at 48 ppm (180 or 228 mg/m3)
Study: 10901114
Drug: toluene at
Approvals — FDA: no, EMA: no, PMDA: no
Description: toluene at 12 ppm (44 or 56 mg/m3)
Study: 10901114
Drug: toluene at
Approvals — FDA: no, EMA: no, PMDA: no
Description: toluene at 48 ppm (180 or 228 mg/m3)
Study: 8929726
Drug: DTPw-HB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw-HB vaccine administered according to a 0, 1.5, 3-month schedule
Study: 26205801
Drug: Intravenous Desferrioxamine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Desferrioxamine, 40 mg/kg/day, 6 days per week for 6 months
Study: 26205801
Drug: Subcutaneous Desferrioxamine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Desferrioxamine, 40 mg/kg/day, 6 days per week 8-12 hours per day for 6 months
Study: 26205801
Drug: Oral Deferiprone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Deferiprone, 75 mg/kg/day in three divided doses daily for 6 months
Study: 26205801
Drug: Oral Deferasirox,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Deferasirox, 30 mg/kg/day in single dose on empty stomach daily for 6 months
Study: 19741188
Drug: high-carbohydrate/high-fiber diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-carbohydrate/high-fiber diet (52% total energy, 28 g/1,000 kcal fiber, low glycemic index 58%)
Study: 17121134
Drug: Continuous MgSO4
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous MgSO4 infusion (12 grams in 500 ml normal saline daily for 12 days)
Study: 17121134
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no MgSO4 infusion)
Study: 11329798
Drug: Verteporfin (Visudyne)
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin (Visudyne) used in conjunction with laser activation (photodynamic therapy) for AMD treatment
Study: 9158305
Drug: PGE2 gel
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 gel (Prepidil) 0.5 mg in 2.5 ml of triacetin gel
Study: 7962672
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg nimodipine orally
Study: 7962672
Drug: 2.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/kg tirilazad mesylate as a 10‐minute intravenous infusion
Study: 7962672
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nimodipine and tirilazad mesylate
Study: 3609067
Drug: Oral dose
Normalized name: Exactamed Oral Dose Syringe 35cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of 10 mg dihydroergosine
Study: 3609067
Drug: Intravenous dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose of 0.75 mg dihydroergosine
Study: 29415825
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (1 g daily)
Study: 29415825
Drug: Metformin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1 g daily)
Study: 29415825
Drug: Control (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (1 g cellulose daily)
Study: 26171380
Drug: Morning aerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning aerobic exercises and medicine
Study: 26171380
Drug: Afternoon aerobic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Afternoon aerobic exercises and medicine
Study: 21812891
Drug: PF-04603629 (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04603629 (70 mg)
Study: 12052991
Drug: Intra-arterial recombinant
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial recombinant prourokinase plus intravenous heparin
Study: 12052991
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin only
Study: 8520194
Drug: IVF with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVF with sperm stimulants (PF alone or PF + 2DA)
Study: 2266066
Drug: Aminophylline injection
Normalized name: aminophylline Injection
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline injection in patients with mild spontaneous attacks
Study: 192560
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg trimeprazine
Study: 192560
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg trimeprazine
Study: 192560
Drug: Withdrawal after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal after 10 mg and 20 mg
Study: 29282267
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and exercise programme for 18 weeks, followed by cognitive behavioural therapy, knee brace, or muscle strengthening for 12 weeks if remission is not achieved
Study: 25782319
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with amlodipine and ramipril
Study: 19888560
Drug: Olanzapine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (7.5 mg) plus mifepristone (600 mg)
Study: 19888560
Drug: Olanzapine plus
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine plus mifepristone (600 mg)
Study: 17568325
Drug: N-acetylcysteine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (150 mg/kg loading dose; 15 mg/kg/hr continuous infusion)
Study: 8085933
Drug: Daily home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily home exercise program aimed at stretching the hamstrings for 4 weeks
Study: 23002126
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m² day 1 q3W)
Study: 23002126
Drug: Vinorelbine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine (25 mg/m² day 1 q2W)
Study: 18171294
Drug: Combined ART
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined ART and IL-2 therapy
Study: 10764713
Drug: Loxiglumide (CCK-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (CCK-A receptor antagonist) with long chain fatty acids
Study: 8612393
Drug: 0.45 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 mg/kg methylnaltrexone plus 0.05 mg/kg morphine
Study: 8612393
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg morphine
Study: 8612393
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus 0.05 mg/kg morphine
Study: 3881608
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (discontinued medication without dietary intervention)
Study: 29229466
Drug: Intravenous electrocoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous electrocoagulation (EC)
Study: 27394382
Drug: High vegetable
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High vegetable and fiber, low-fat diet with daily physical activity goals
Study: 16722866
Drug: Topical antifungal
Normalized name: Imidazole and triazole derivatives, topical antifungals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antifungal nail lacquer (ciclopirox 8%)
Study: 12848775
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg x m(‐2) with zosuquidar 3HCl
Study: 12848775
Drug: Paclitaxel 225
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 225 mg x m(‐2) with zosuquidar 3HCl
Study: 12848775
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg x m(‐2) alone
Study: 10535716
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) administered at home (0.1 mL per kg body weight subcutaneously twice daily)
Study: 10535716
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin administered in hospital
Study: 10535716
Drug: Subcutaneous calcium
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous calcium heparin (SCHep) administered at home (0.5 mL bid)
Study: 10535716
Drug: Subcutaneous calcium
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous calcium heparin (SCHep)
Study: 8559429
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IgIV) treatment
Study: 14699594
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange (PE) treatment
Study: 6840181
Drug: Intravenous melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous melphalan (10 mg)
Study: 6840181
Drug: Oral melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral melphalan (10 mg)
Study: 29652273
Drug: Milrinone infusion
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone infusion 0.5 μg/kg/min without a loading dose followed by 0.5‐0.75 μg/kg/min
Study: 29652273
Drug: Milrinone infusion
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone infusion with loading dose 50 μg/kg over 10 min followed by 0.5‐0.75 μg/kg/min
Study: 27338218
Drug: 150% portion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150% portion of milk (275 g)
Study: 22045830
Drug: Ibutilide 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide 1 mg intravenously
Study: 16926775
Drug: saquinavir SGC/ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: saquinavir SGC/ritonavir (1600 mg/100 mg)
Study: 16926775
Drug: efavirenz (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: efavirenz (600 mg)
Study: 10769437
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (500 mg calcium daily)
Study: 8315266
Drug: Nocturnal oral
Normalized name: Nocdurna Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocturnal oral glucose supplementation
Study: 2961314
Drug: Intravenous (I.V.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (I.V.) 5-fluorodeoxyuridine (FUDR)
Study: 7044608
Drug: Medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical management with early intensive therapy including nitrates and beta-blocking agents
Study: 26073393
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (unspecified)
Study: 20519962
Drug: hu12F6mu (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: hu12F6mu (2.5, 5, or 10 mg)